All In MedTech

Device Trial Radar · NCT02317185

Clinical Evaluation of GENEX® DS in Instrumented Posterolateral Fusion

CLINICAL EVALUATION OF GENEX® DS IN INSTRUMENTED POSTEROLATERAL FUSION

Last checked: Nov 20, 2026Latest source record: Apr 19, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

2

Actual

Start

Dec 2014

Primary completion

Dec 2016

Study completion Dec 2016

Sponsor

Lead sponsor
Spine WaveNot on our public-company list
Sponsor type
Industry
First posted
Dec 15, 2014

More device trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The overall goal of this clinical study is to characterize the fusion rate of geneX® ds bone graft substitute in comparison to autograft, which is considered the gold standard for posterolateral fusion. Assessments are made using AP and Lateral x-rays, F/E x-rays, and CT scans geneX® ds has been cleared by the FDA for use in these procedures; however this study will allow more detailed characterization of geneX® ds performance in the long-term (1 year). By using the patient as their own control, direct comparison to autograft can be performed while minimizing other variables.

Conditions

  • Degenerative Disc Disease
  • Spondylolisthesis
  • Stenosis

Interventions

  • genex bone graft with bone graftDevice

  • autogenous bone graftOther

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FusionTime frame: 1 year

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital for Special Surgery

    New York, New York

  • Carolina Neurosurgery and Spine Associates

    Charlotte, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.